Gapping down
In reaction to disappointing earnings/guidance:
- UBS -1.5%
M&A news:
- CELG -1.1% (to acquire JUNO for $87/share)
Other news:
- VICL -27.3% (Vical Astellas Pharma report Top-Line results for Phase 3 trial of Cytomegalovirus Vaccine; did not meet primary end-point)
- FORD -6.8% (modestly pulling back after Friday's 138% move)
- TEVA -2% (announces that a Phase III registration study evaluating subcutaneously administered reslizumab (110 mg) in a pre-filled syringe did not meet its primary endpoint)
Analyst comments:
- GE -0.5% (downgraded to Neutral from Buy at BofA/Merrill)
- AAPL -0.6% (downgraded to Neutral from Overweight at Atlantic Equities)
- AXP -0.8% (downgraded to Neutral from Buy at Guggenheim)
- FCX -1% (downgraded to Neutral from Outperformer at CIBC)
- CBS -1.5% (downgraded to Equal-Weight from Overweight)
- PANW -1.7% (downgraded to Neutral from Buy at Goldman)
- ESPR -1.9% (downgraded to Neutral from Buy at Citigroup)
- LLY -2.1% (downgraded to Underperform from Neutral at Credit Suisse)
